Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Oxytocin for Residual Symptoms in Schizophrenia
NCT02144155Terminated
- Sponsor
- University of California, San Diego
- Start
- Mar 2012
- Primary completion
- Dec 2014
- Modality
- Peptides
- Countries
- 1
01
Overview
Randomised, open-label trial in schizophrenia comparing Oxytocin: 24 IU - 168 IU with Vehicle placebo (2 arms). Primary endpoint: Positive and Negative Syndrome Scale at 28 weeks. Started Mar 2012; status: terminated.
02
Drugs
oxytocin
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02144155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02144155.